Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Live Cell Imaging Ready to Transform Disease Diagnostics and Drug Discovery

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Breakthroughs in fluorescent applications, electronics, optics, and molecular biology have made live cell imaging technologies more accessible to life scientists trying to better understand biologic dynamics and visualize cellular events in living organisms, according to recent market research. The introduction of “omics” technologies and nanotechnologies into mainstream medicine has already enabled commercial lab-on-a-chip microfluidics systems that analyze cells, DNA, RNA, and proteins. As live cell imaging evolves, it will become a key player in disease diagnostics and drug discovery processes.

New analysis from Frost & Sullivan (Mountain View, CA, USA), an international growth consultancy company, found that live cell imaging technologies will have a large number of niche applications in cancer research, cell biology, developmental biology, and neuroscience. Currently available technologies include live cell-based tests systems and molecular models including high-resolution imaging systems.

“The principal challenges to successful live cell imaging are microscopic settings optimization, fluorescent components selection, and culture environment maintenance,” said technical insights senior research analyst Cecilia Van Cauwenberghe. “Parallel advances in the field of cell culturing will also be critical to ensure accurate, real-time results.”

Utilizing live cell imaging along with fixed cell tests before the former totally replaces the latter, will lower costs and lessen throughput times. Equipment combining microscopes with cell culture incubators is already being marketed, facilitating affordable three-dimensional (3D), real-time assessment, multiplexing, and automation capabilities.

Tightly integrated systems can provide new benchmarks of precision and degrees of efficiency for the study of individual and small groups of live cells. They will enable innovative new ways for multiple cell analysis, simultaneous processing, and multi-day time lapse live cell imaging. However, it is essential that government patent systems protect these innovations, especially since new players in the market emerge from different start points. Similarly, measures must be taken to reduce uncertainty regarding reimbursements, and to establish frameworks assuring balance among tier I companies, small and medium enterprises, and start-ups developing innovative technologies.

“Intellectual property regimes promoting integration between academia and industry in order to deliver new solutions are necessary,” concluded Ms. Cauwenberghe. “Drug producers must collaborate with other stakeholders to translate live cell imaging innovations into clinically meaningful tests that can be used for diagnosis, prognosis and drug development.”

Related Links:

Frost & Sullivan



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.